---
title: "Wells Fargo Remains a Buy on Kyverna Therapeutics, Inc. (KYTX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286234948.md"
description: "Wells Fargo analyst Derek Archila has maintained a Buy rating on Kyverna Therapeutics, Inc. (KYTX) with a price target of $33.00, while the stock closed at $10.23. Archila, a 5-star analyst, has an average return of 20.1% and a 53.67% success rate. The consensus on Kyverna is a Strong Buy with an average price target of $29.00, indicating a potential upside of 183.48%. William Blair also supports a Buy rating on the stock."
datetime: "2026-05-13T09:38:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286234948.md)
  - [en](https://longbridge.com/en/news/286234948.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286234948.md)
---

# Wells Fargo Remains a Buy on Kyverna Therapeutics, Inc. (KYTX)

Wells Fargo analyst Derek Archila maintained a Buy rating on Kyverna Therapeutics, Inc. yesterday and set a price target of $33.00. The company’s shares closed yesterday at $10.23.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Archila is a 5-star analyst with an average return of 20.1% and a 53.67% success rate. Archila covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Incyte, and Argenx Se.

Currently, the analyst consensus on Kyverna Therapeutics, Inc. is a Strong Buy with an average price target of $29.00, a 183.48% upside from current levels. In a report released today, William Blair also maintained a Buy rating on the stock with a $0.00 price target.

### Related Stocks

- [KYTX.US](https://longbridge.com/en/quote/KYTX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [RYTM.US](https://longbridge.com/en/quote/RYTM.US.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md)
- [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md)
- [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md)
- [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md)
- [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md)
- [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md)
- [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Kyverna announces strong Phase 2/3 CAR T neuroimmunology data](https://longbridge.com/en/news/283657041.md)